Gerot-Lannacher
Gerot-Lannacher (GL Pharma) is an Austrian specialty pharmaceutical company that develops, manufactures, and commercializes branded and generic drugs for severe and chronic conditions, including substitution therapy for drug addiction, selling through Austrian healthcare channels and international licensing partners.
- Company typePrivate
- Founded-
- HeadquartersLannach, Austria
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Gerot-Lannacher does
Gerot-Lannacher, operating commercially as GL Pharma, is an Austrian pharmaceutical company headquartered in Lannach, Austria, that develops, manufactures, and commercializes both branded pharmaceuticals and generic drugs. The company focuses on innovative and generic proprietary developments in specialized indication areas, with particular expertise in substitution therapy medications for drug addiction treatment. Its portfolio addresses severe and chronic conditions and is distributed through Austria's healthcare supply chain via general practitioners, pharmacists, and pharmaceutical wholesalers, with international reach pursued through licensing partnerships.
The company's go-to-market is B2B sales-led, targeting vertical healthcare segments rather than end consumers. Revenue is generated through the development, production, and commercialization of pharmaceutical products, supplemented by out-licensing of proprietary products to international partners. Pricing is not publicly disclosed. The company maintains a web-based resource center distributing product catalogues and reports, and engages in top-of-funnel brand presence through LinkedIn, Instagram, and Facebook.
Operationally, the company functions as a privately held specialty pharmaceutical manufacturer with no disclosed parent company, subsidiaries, or funding rounds. Corporate social media and website activity (© 2026) confirm active operations. No information on headcount, financial performance, leadership, or M&A activity is available in the source data, representing a material information gap for investors.
Gerot-Lannacher firmographics
Firmographics- Name
- Gerot-Lannacher
- Legal name
- Gerot-Lannacher
- Website
- https://gl-pharma.at
- Company type
- Private
- Operating status
- Operating
- Short description
- Gerot-Lannacher (GL Pharma) is an Austrian specialty pharmaceutical company that develops, manufactures, and commercializes branded and generic drugs for severe and chronic conditions, including substitution therapy for drug addiction, selling through Austrian healthcare channels and international licensing partners.
- Ownership category
- akta.pro rank
Gerot-Lannacher industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
- akta.pro secondary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where Gerot-Lannacher is headquartered
LocationHeadquarters
- HQ city
- Lannach
- HQ country
- Austria
- HQ region
- Europe
Offices1 record
Markets served
Gerot-Lannacher business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
Revenue model
- Pharmaceutical Products: Revenue generated from development, production, and commercialization of brand name pharmaceuticals and generic drugs for treatment of severe and chronic conditions. Products are distributed through healthcare sector partners including general practitioners, pharmacists, and pharmaceutical wholesalers.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Gerot-Lannacher product offering
Product offeringCore offering
Gerot-Lannacher (GL Pharma) develops, produces, and commercializes branded pharmaceuticals and generic medicines focused on treating severe and chronic disease states. The portfolio includes medication-assisted substitution therapy products used in the treatment of drug addiction. Distribution is conducted through general practitioners, pharmacists, and pharmaceutical wholesalers, with additional licensing arrangements for international partners.
Product overview
GL Pharma operates as a pharmaceutical company developing, producing, and commercializing both unique brand name products and generic pharmaceuticals. The company focuses on innovative and generic proprietary developments in specialized indication areas for the treatment of severe and chronic conditions. Their portfolio includes brand name pharmaceuticals and generics distributed in Austria and internationally, with specific expertise in substitution therapy for drug addiction treatment. They partner with general practitioners, pharmacists, and pharmaceutical wholesalers as suppliers to Austria's healthcare sector.
Differentiator
Problem solved
Functional benefit
Products and services
- Branded Pharmaceuticals
Companies that use Gerot-Lannacher
Customer profileSegments3 records
Ideal customer profiles2 records
Gerot-Lannacher technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Gerot-Lannacher partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Licensing PartnerscoreGL Pharma offers licensing opportunities for their pharmaceutical products, allowing international partners to commercialize their innovative medicines in different markets.
- Research & Development PartnerscoreCollaborative partnerships focused on innovative and generic proprietary developments in specialized indication areas. The company is committed to continuous investment in pharmaceutical research and development.
Scale indicators1 record
Recent moves4 records
Expansion highlights5 records
Gerot-Lannacher competitors and assessment
Company assessmentDirect peers
- Polpharma: Polish generics and branded-generics manufacturer with European distribution and growing specialty portfolio. Comparable hybrid model targeting CEE and broader EU markets with manufacturing-led economics.
- KRKA: Slovenian manufacturer of generic and specialty branded pharmaceuticals sold primarily across CEE and Western Europe. Comparable portfolio mix, manufacturing-led model, and growing focus on higher-value specialty indications.
- Gedeon Richter: Hungarian pharma group combining branded generics with proprietary innovation, including specialty CNS and women's health franchises. Comparable hybrid model, EU manufacturing base, and international licensing strategy.
- STADA Arzneimittel: German-headquartered private-equity-owned pharma combining generics and specialty branded products across Europe. Highly comparable dual branded-generics model, similar mid-cap European footprint, and overlapping distribution through wholesalers and pharmacies.
- Camurus: Swedish specialty pharma with a leading franchise in opioid dependence and substitution therapy. Overlaps directly with GL Pharma's substitution-therapy specialty and EU focus on addiction medicine.
- Indivior: UK/US specialty pharma focused on opioid dependence and addiction treatment. Direct overlap with GL Pharma's substitution-therapy franchise and chronic-condition specialty positioning.
Broad incumbents
- Sandoz (Novartis): Global generics and biosimilars leader spun out of Novartis. Overlaps with GL Pharma's generics and selective specialty lines, but operates at vastly greater scale and geographic breadth.
- Teva Pharmaceutical Industries: World's largest generics manufacturer with branded specialty franchises including CNS and pain. Broad overlap with GL Pharma's dual branded-generics strategy, but at global incumbent scale.
- Viatris: Global pharma formed from Mylan-Upjohn combining established branded specialty with broad generic portfolio. Competes across many of the same therapeutic areas and distribution channels as GL Pharma, particularly in Europe.
Emerging players
- Zambon: Italian privately held pharma with branded specialty in CNS, pain, and rare diseases alongside generics. Comparable European mid-cap footprint and growing focus on specialty therapeutics adjacent to GL Pharma's portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Gerot-Lannacher social profiles
Digital presenceGerot-Lannacher financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gerot-Lannacher leadership team
Management profileNumber of profiles
Gerot-Lannacher funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gerot-Lannacher M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gerot-Lannacher
What does Gerot-Lannacher do?
Gerot-Lannacher (GL Pharma) develops, produces, and commercializes branded pharmaceuticals and generic medicines focused on treating severe and chronic disease states. The portfolio includes medication-assisted substitution therapy products used in the treatment of drug addiction. Distribution is conducted through general practitioners, pharmacists, and pharmaceutical wholesalers, with additional licensing arrangements for international partners.
Is Gerot-Lannacher a public or private company?
Gerot-Lannacher is a private company. It is classified as unknown and is currently operating.
When was Gerot-Lannacher founded?
Gerot-Lannacher was founded in -1.
Where is Gerot-Lannacher based?
Gerot-Lannacher is headquartered in Lannach, Austria, in the Europe region.
How does Gerot-Lannacher make money?
One revenue line is on record: pharmaceutical Products.
Who are Gerot-Lannacher's main competitors?
Direct peers on record are Polpharma, KRKA, Gedeon Richter, STADA Arzneimittel, Camurus and Indivior. Broad incumbents are Sandoz (Novartis), Teva Pharmaceutical Industries and Viatris. Zambon is listed as an emerging player.
Does Gerot-Lannacher have an API?
No public API is recorded for Gerot-Lannacher.
What industry is Gerot-Lannacher in?
Gerot-Lannacher's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.